Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Multicenter phase II study of MKC-1 initiated in breast cancer
February 14th, 2006
EntreMed, Inc., (ENMD) has initiated phase II studies with MKC-1. The single-arm, open-label study will be conducted at approximately 15 centers in the United States and will enroll patients with advanced or metastatic breast cancer who have failed conventional therapies. MKC-1 is a novel, orally- active, small molecule cell cycle inhibitor with a unique mechanism of action. Specifically, MKC-1 arrests cellular mitosis by inhibiting an intracellular target important in cellular trafficking that has been shown to be involved in cell division. MKC-1 belongs to a novel class of antimitotics and apoptosis-inducers with in vitro efficacy against a wide...
Source: Cancer Weekly (2006-02-14)
|
